glp-1 perimenopause Microdosing for Perimenopause: Benefits & Risks HRT + GLP-1 for Perimenopause

This shift causes temporary constipation until your intestinal bacteria and transit time reach a new equilibrium, usually within 48 weeks

Key Difference: Tirzepatide (Mounjaro/Zepbound): Dual GIP/GLP-1 agonist Semaglutide (Wegovy/Ozempic): GLP-1 agonist only Effectiveness Difference: Tirzepatide: 15-22% average body weight loss Semaglutide: 10-15% average body weight loss Semaglutide is less potent but still highly effective and significantly more affordable than brand-name tirzepatide

As branded GLP-1 medications have remained difficult to access and expensive, demand for compounded alternatives has grown sharply

Investigational GLP-1 patches use specialised technologies such as microneedles to deliver large peptide molecules across the skin barrier

Dont Buy for Single Use

GLP-1 Patent Timelines: When Will Generics Be Available